TMO
Thermo Fisher Scientific Inc.
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 9.32B | 7.82B | 8.67B | 8.41B | 9.15B | 9.31B | 8.29B | 4.97B | 4.54B | 4.01B | 3.26B | 2.94B | 2.62B | 2.01B | 2.04B | 1.69B | 1.50B | 1.66B | 1.42B | 1.48B |
| 1.73B | 1.53B | 1.40B | 1.48B | 2.24B | 2.52B | 1.47B | 0.93B | 0.76B | 0.51B | 0.44B | 0.42B | 0.43B | 0.28B | 0.32B | 0.26B | 0.25B | 0.20B | 0.26B | 0.18B | |
| Free cash flow | 7.60B | 6.29B | 7.27B | 6.93B | 6.91B | 6.79B | 6.82B | 4.05B | 3.79B | 3.50B | 2.81B | 2.52B | 2.19B | 1.73B | 1.72B | 1.43B | 1.25B | 1.46B | 1.16B | 1.31B |
| Depreciation and amortization | 3.11B | 2.78B | 3.11B | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 1.00B | 0.98B | 0.86B | 0.74B | 0.76B | 0.79B | 0.76B |
| Stock-based compensation | 345M | 310M | 301M | 278M | 307M | 230M | 196M | 181M | 181M | 159M | 133M | 125M | 117M | 91M | 78M | 80M | 82M | 67M | 57M | 51M |
| Buybacks | 4.04B | 3.00B | 4.00B | 3.00B | 3.00B | 2.00B | 1.50B | 1.50B | 0.50B | 0.75B | 1.25B | 0.50B | 0 | 90M | 1.15B | 1.34B | 1.01B | 0.41B | 0.19B | 0.90B |
| Dividends paid | 673M | 636M | 583M | 523M | 455M | 395M | 337M | 297M | 266M | 237M | 238M | 241M | 235M | 216M | 142M | 0 | — | — | — | — |
| Dividends per share | 1.84 | 1.72 | 1.56 | 1.40 | 1.20 | 1.04 | 0.88 | 0.76 | 0.68 | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 0.54 | 0.00 | 0.00 | — | — | — |
| Free cash flow margin | 16.0% | 14.1% | 16.9% | 16.2% | 15.4% | 17.3% | 21.2% | 15.8% | 15.5% | 16.7% | 15.4% | 14.8% | 13.0% | 13.2% | 13.8% | 12.4% | 12.1% | 14.7% | 11.0% | 13.4% |